MyFinsight
Home
Blog
About
Proceeds from exercise of
series a warrants into...
$25,212K
Proceeds from exercise of
options and employee...
$7K
(-46.15%↓ Y/Y)
Proceeds from sale of
shares of common stock...
$1K
Net cash provided by
financing activities
$21,601K
(166061.54%↑ Y/Y)
Canceled cashflow
$3,619K
Net (decrease)
increase in cash, cash...
-$82,737K
Canceled cashflow
$21,601K
Sales/maturities of marketable
securities
$16,000K
(-40.74%↓ Y/Y)
Stock-based compensation
expense
$1,431K
(-42.83%↓ Y/Y)
Increase in fair value of
royalty monetization...
-$872K
Noncash operating lease
expense
$318K
(-45.36%↓ Y/Y)
Depreciation and
amortization expense
$16K
(-93.33%↓ Y/Y)
Proceeds from sale of
shares of common stock...
-$3,619K
Net cash (used in)
provided by investing...
-$86,740K
(-605.63%↓ Y/Y)
Canceled cashflow
$16,000K
Net cash used in
operating activities
-$17,594K
(-16.87%↓ Y/Y)
Effect of exchange
rates on cash, cash...
-$4K
Canceled cashflow
$2,637K
Purchase of marketable
securities
$102,740K
(943.58%↑ Y/Y)
Net loss
-$15,008K
(-0.60%↓ Y/Y)
Prepaid expenses and
other current assets
$1,775K
(102.16%↑ Y/Y)
Accounts payable
-$1,508K
(-298.42%↓ Y/Y)
Noncash consideration
received in licensing...
$733K
Deferred revenue
-$718K
(-200.00%↓ Y/Y)
Change in accrued
interest and accretion of...
-$500K
(-55.28%↓ Y/Y)
Back
Back
Cash Flow
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)
source: myfinsight.com